RoACTEMRA (tocilizumab, known as ACTEMRA outside of the EU) is the first interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody developed for the treatment of RA (rheumatoid arthritis) and is a novel approach to help tackle this debilitating disease. IL-6 has been identified as having a fundamental role in the inflammation process in RA.
RoACTEMRA, in combination with methotrexate (MTX), is indicated for the treatment of adult patients with moderate to severe RA who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists. In these patients, RoACTEMRA can be given as monotherapy in cases of intolerance to methotrexate (MTX) or where continued treatment with MTX is inappropriate.
Looking for more detailed information?
For regulatory reasons we are not able to provide further details on our products on this website, but more information may be available on our local website.
Please choose your country of residence to access available information in your language.